Ticker brief · 2026-08-16
LLY ELI LILLY & CO
Lilly bulls retain control as safety and oral-share risks surface
Consumer, Non-cyclical · Pharmaceuticals
Lean: bullishlast close
$1,175
1 day
-0.1%
14 days
-0.5%
mkt cap
$1.1T
signals 14d
392
authors 14d
188
crowd 14d
+0.1σ
The lean remains bullish: credible fundamental voices favor Lilly’s obesity leadership, while proven technical traders bought constructive post-earnings action. The late-week shift was an emerging retatrutide safety challenge centered on an 11% phase-two tachycardia or arrhythmia risk. Bullish exposure is crowded around 1230-1240 breakout triggers and short-dated calls, making failed-breakout risk unusually sharp.
BULL CAMP
Lilly’s efficacy, manufacturing, distribution and pricing advantages should preserve obesity leadership, while U.K. oral approval and accelerating Foundayo prescriptions broaden the franchise. Strong earnings momentum and multiple technical bases reinforce the fundamental thesis.
Key voices@bioinvestor24MEDIUM-HIGHA-0.45@ResearchPulse1MEDIUM-HIGHB+1.48@investseekersMEDIUMB-0.65@philrosennHIGHC-0.95@VladBastionMEDIUM-HIGHB-1.80
“Rapid revenue and earnings growth leave Lilly’s generational business fundamentals underappreciated.”— @philrosenn · tweet ↗
BEAR / SKEPTIC
The bear case rests on Novo’s 84%-89% oral-obesity share, lackluster 13.4% and 11% oral outcomes, premium valuation and emerging retatrutide cardiac-safety concerns. A crowded breakout could unwind if 1230-1240 fails.
Key voices@KontraInvestMEDIUM-HIGHA+0.93@bioinvestor24MEDIUM-HIGHA-0.45@ResearchPulse1MEDIUM-HIGHB+1.48@SchwabNetworkHIGHC-2.08@kpak82MEDIUM-HIGHC-0.13
“An 11% phase-two tachycardia or arrhythmia risk raises uncertainty about Lilly’s corresponding retatrutide trial rate.”— @bioinvestor24 · tweet ↗
Hypotheses14direction · basis · magnitude · supporters — NEW = first seen this week
▲Lilly’s efficacy, pricing, supply and distribution advantages should preserve injectable obesity leadership and sustain outsized franchise growth.
@bioinvestor24MEDIUM-HIGHA-0.458s · insight@ResearchPulse1MEDIUM-HIGHB+1.482s · insight@investseekersMEDIUMB-0.653s · insight@ManOnThePenB-1.592s@philrosennHIGHC-0.951s@VladBastionMEDIUM-HIGHB-1.801s · insight+1 more
▲U.K. approval of Lilly’s once-daily oral GLP-1 expands Foundayo internationally and enables direct competition with Novo Nordisk.
@investseekersMEDIUMB-0.651s · insight@CNBCHIGHC+1.092s@himshouseLOW-MEDIUMC+1.001s@tig88411109MEDIUM-HIGHB+1.391s · insight@WallStDiariesLOW-MEDIUMC-0.201s@ftr_investorsMEDIUM-HIGHC-0.611s+1 more
▲Foundayo’s faster recent prescription growth suggests Lilly is beginning to take oral-obesity share despite its smaller launch base.
@investseekersMEDIUMB-0.654s · insight@KontraInvestMEDIUM-HIGHA+0.933s · insight@ResearchPulse1MEDIUM-HIGHB+1.482s · insight@semodoughMEDIUM-HIGHC-3.011s
▲A GLP-1 market exceeding $100B provides enough category growth for Lilly’s obesity franchise to compound despite intensifying competition.
@bioinvestor24MEDIUM-HIGHA-0.452s · insight@KontraInvestMEDIUM-HIGHA+0.931s · insight@semodoughMEDIUM-HIGHC-3.012s@SVTrivoMEDIUM-HIGHC-2.271s
▲A sustained break above 1230-1240 could extend Lilly’s post-earnings advance toward 1255, 1340 and eventually $1,506.70.
@TheMarketRavenMEDIUMC-0.534s@RemzztradesMEDIUM-HIGHC+0.434s@ProblemSniperMEDIUM-HIGHC+0.742s@ElliottForecastMEDIUMC-0.672s@IBDinvestorsHIGHB+1.051s@ivanhoffMEDIUM-HIGHC-1.312s+2 more
▲Lilly’s 31% EPS beat and raised guidance confirm stronger near-term earnings momentum and validate the post-earnings re-rating.
▲Lilly’s lawsuits and regulatory referrals against illicit retatrutide sellers should protect pipeline control and reduce unauthorized-market leakage.
@investseekersMEDIUMB-0.652s · insight@ManOnThePenB-1.593s@CNBCHIGHC+1.091s@WSJMEDIUM-HIGHA-0.322s · insight@tenet_researchMEDIUM-HIGHC-0.962s@fwpharmaMEDIUM-HIGHB+0.981s
▼Retatrutide may carry clinically material tachycardia, arrhythmia and cardiac-death risks that could constrain adoption or disrupt development.
@bioinvestor24MEDIUM-HIGHA-0.452s · insight
▼Tirzepatide’s reported black-box warning introduces a discrete safety overhang for Lilly’s established obesity and diabetes franchise.
@ResearchPulse1MEDIUM-HIGHB+1.481s · insight
▲Once-monthly tirzepatide development could improve convenience and extend Lilly’s lifecycle advantage across the segmented obesity market.
@ResearchPulse1MEDIUM-HIGHB+1.481s · insight@bioinvestor24MEDIUM-HIGHA-0.451s · insight
▲LillyPod’s launch strengthens the proprietary TuneLab platform and could improve Lilly’s internal AI-enabled drug-discovery productivity.
@nanalyzetweetsMEDIUM-HIGHB+0.002s · insight
▼Novo’s 84%-89% oral-obesity prescription share indicates category dominance and limits Lilly’s near-term Foundayo share capture.
@KontraInvestMEDIUM-HIGHA+0.934s · insight@bioinvestor24MEDIUM-HIGHA-0.452s · insight@ResearchPulse1MEDIUM-HIGHB+1.482s · insight
▼Lilly’s premium valuation and crowded positioning leave shares vulnerable to de-rating or a failed breakout despite strong fundamentals.
@TheMarketRavenMEDIUMC-0.532s@SchwabNetworkHIGHC-2.081s@kpak82MEDIUM-HIGHC-0.131s@PatrickWalker56HIGHC-0.041s@KontraInvestMEDIUM-HIGHA+0.931s · insight
◆Capital is rotating toward healthcare and non-AI diversification, increasing attention on Lilly without independently resolving its valuation debate.
@twinsight_xMEDIUM-HIGHC+0.961s@BichonFrise_JTCLOW-MEDIUMC-0.752s@TravisBiziorekMEDIUMC-2.391s@TradeCyclesLOW-MEDIUMC-0.511s
Direct calls5authors taking explicit directional positions
@ElliottForecastMEDIUMC-0.67
Remain long LLY for a rally toward $1,506.70 or higher.
@ivanhoffMEDIUM-HIGHC-1.31
Bought LLY this morning as it acts constructively after earnings.
@RemzztradesMEDIUM-HIGHC+0.43
Buy weekly 1250/1270 calls or next week's 1300 call, targeting 1340.
@capestrategicoMEDIUMC+0.17
Add another 1% of the portfolio to LLY.
@aboutheoptionsMEDIUMC
LLY $900 put remains actionable.
Sellside activity1
Bank of America noteResearch highlighted an Eli Lilly market opportunity potentially larger than the U.S.
News / data points5discrete events + data quoted by authors
@CNBCHIGHC+1.09
Foundayo secured Lilly’s first non-U.S. approval, opening direct U.K. competition with Novo Nordisk.
@Venu_7_MEDIUM-HIGHB+0.10
Lilly delivered a 31% EPS beat, raised guidance and retained constructive price action.
@investseekersMEDIUMB-0.65
Prescription data showed weakening Oral Wegovy share and continued Foundayo growth.
@ResearchPulse1MEDIUM-HIGHB+1.48
Wegovy-pill Symphony volume reached 133,143, up 1.5%, while Foundayo increased 10.7%.
@ManOnThePenB-1.59
Lilly sued six retatrutide distributors and referred more than 200 parties to authorities.
Position disclosures3skin in the game
@DrStoxxMEDIUM-HIGHC-1.58
Existing LLY long after a strong trading day.
@KunnuInvestsLOW-MEDIUMC-1.52
Long-term LLY holding.
@TheMarketRavenMEDIUMC-0.53
Losing LLY trade sized to avoid material account damage.
Desk readconvergence assessment
Views converge on Lilly’s injectable leadership and broad obesity-market growth, but diverge sharply on oral share, valuation and retatrutide safety. The bull camp has broader credible support, although several prominent bulls have negative trader_score_20 readings; the strongest oral-share bear, KontraInvest, carries a 1.9 score, while the stark technical bear kpak82 carries 2.22. Sustained Foundayo share gains and clean retatrutide cardiac data would strengthen the bull case; failure at 1230-1240 or confirmation of clinically material arrhythmia risk would reverse it.
Options inteloptions-surface reads · latest available day per source
| metric | reading | context |
|---|---|---|
| IV — ATM 30d | 34% mid · 40 pctile own 1y | IV/HV 0.86× (as of 2026-08-06) |
| Skew — 25Δ RR 30d | -0.021 40 pctile own 1y | balanced vs own range |
| Net dealer OI (NDOI) | +0.80 elevated | 5-session Δ -0.06 (as of 2026-07-06) |
| OI alarm | quiet | last alarm 2025-08-08 (z=6.1) |
Sentiment — last 14 days
daily mean sentiment, 2026-08-14 → 2026-08-28 · now +0.41 (−1 bearish … +1 bullish)
Who spoke188
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @bioinvestor24 | A | -0.45 | 35 | +0.05 |
| @investseekers | B | -0.65 | 34 | +0.21 |
| @ResearchPulse1 | B | +1.48 | 11 | +0.10 |
| @ElliottForecast | C | -0.67 | 9 | +0.75 |
| @himshouse | C | +1.00 | 8 | +0.17 |
| @KontraInvest | A | +0.93 | 7 | +0.03 |
| @MartyChargin | C | -0.27 | 7 | +0.37 |
| @EmmanuelInvest | C | -1.11 | 6 | +0.27 |
| @kpak82 | C | -0.13 | 6 | -0.62 |
| @twinsight_x | C | +0.96 | 5 | +0.63 |
| @ScrooogeUncle | C | +0.04 | 5 | +0.72 |
| @BioStocks | C | -3.02 | 4 | +0.29 |
| @Arturraposo1R | B | -0.66 | 4 | +0.06 |
| @IngJuanPa7 | B | -1.61 | 4 | +0.10 |
| @fwpharma | B | +0.98 | 4 | +0.30 |
| @ManuelAir_ | C | -0.52 | 4 | +0.58 |
| @everytimeicash | B | +0.23 | 4 | +0.57 |
| @NickDrendel | C | -1.09 | 4 | +0.05 |
| @tokens | C | +0.40 | 4 | +0.21 |
| @kulturdesken | B | -0.99 | 3 | +0.47 |
| @semodough | C | -3.01 | 3 | -0.05 |
| @MarketMaestro1 | C | -2.46 | 3 | +0.75 |
| @singlesdoubles | C | -1.28 | 3 | +0.12 |
| @enrichtrades | C | -0.62 | 3 | +0.20 |
| @Source_options | C | +0.34 | 3 | +0.62 |
Recent signals30of 392 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-28 | @himshouse | -0.10 | Unverified rumor says a large 503B pharmacy restarted GLP-1 production | — | tweet ↗ |
| 2026-08-28 | @himshouse | +0.05 | Reports 222,000 units of unapproved retatrutide in a U.S.-bound shipment | — | tweet ↗ |
| 2026-08-28 | @brent_e_trader | +0.45 | Discloses existing sold puts, realized gains and remaining exposure while expressing interest in future calls after a drop. | — | tweet ↗ |
| 2026-08-28 | @bullishchart | +0.50 | Eli Lilly received regulatory approval for a new Mounjaro use. | — | tweet ↗ |
| 2026-08-28 | @Analysistock | -0.40 | Weekly heat-map review highlights technology/software leadership and healthcare weakness. | — | tweet ↗ |
| 2026-08-28 | @ScrooogeUncle | +0.70 | Uses celebratory symbols and a rocket to express strong bullish enthusiasm for LLY. | — | tweet ↗ |
| 2026-08-28 | @bioinvestor24 | +0.55 | Cites prescription data favoring LLY and warns NVO's competitive and revenue position could deteriorate rapidly. | — | tweet ↗ |
| 2026-08-28 | @ScrooogeUncle | +0.65 | Describes LLY as delivering repeated wins. | — | tweet ↗ |
| 2026-08-28 | @bioinvestor24 | -0.05 | Reports encouraging informal VKTX Phase 3 tolerability and weight-loss observations versus competing therapies. | — | tweet ↗ |
| 2026-08-28 | @BiopharmIQ | +0.50 | Biotech open summary pairs stock moves with clinical, regulatory and financing events | — | tweet ↗ |
| 2026-08-28 | @investseekers | +0.20 | Reports legal and enforcement actions against counterfeit weight-loss drugs. | — | tweet ↗ |
| 2026-08-28 | @EmmanuelInvest | +0.50 | FDA approved an expanded cardiovascular-risk-reduction indication for Mounjaro. | — | tweet ↗ |
| 2026-08-28 | @investseekers | +0.35 | Compares explicit weekly prescription volumes and obesity-market shares. | — | tweet ↗ |
| 2026-08-28 | @TBU12345678 | +0.45 | Argues AI value must shift from semiconductors toward users, favoring drug discovery and bioprocessing. | — | tweet ↗ |
| 2026-08-28 | @FiercePharma | +0.45 | Reports Lilly's oral GLP-1 prescriptions crossing 40,000. | — | tweet ↗ |
| 2026-08-28 | @investseekers | +0.00 | Points to an updated visual tracking both oral obesity-drug launches. | — | tweet ↗ |
| 2026-08-28 | @tokens | +0.50 | Reports FDA approval expanding Mounjaro's cardiovascular indication. | — | tweet ↗ |
| 2026-08-28 | @OzmosiHealth | +0.50 | FDA approves Mounjaro to reduce cardiovascular risk in adults with type 2 diabetes. | — | tweet ↗ |
| 2026-08-28 | @ScrooogeUncle | +0.50 | Celebratory ticker-only expression conveys a positive view on LLY. | — | tweet ↗ |
| 2026-08-28 | @investseekers | +0.25 | Reports and compares new weekly prescription data for both drugs. | — | tweet ↗ |
| 2026-08-28 | @LouBasenese | +0.80 | Expects expanding GLP-1 approvals, identifies LLY as the winner and NVO as a value trap. | — | tweet ↗ |
| 2026-08-28 | @robertojirusta | +0.50 | FDA approved Mounjaro to reduce major cardiovascular-event risk in adults with type 2 diabetes. | — | tweet ↗ |
| 2026-08-28 | @OpenOutcrier | +0.50 | FDA expanded Mounjaro's label to reducing cardiovascular risk. | — | tweet ↗ |
| 2026-08-28 | @PolymarketMoney | +0.50 | Reports FDA approval of an expanded cardiovascular-risk indication for Mounjaro. | — | tweet ↗ |
| 2026-08-28 | @TamirTiko2110 | +0.50 | Reports FDA approval of Mounjaro to reduce cardiovascular risk. | — | tweet ↗ |
| 2026-08-28 | @investseekers | +0.50 | FDA expanded Mounjaro's label to reduce major cardiovascular-event risk. | — | tweet ↗ |
| 2026-08-28 | @CardyTruster | +0.50 | Reports FDA approval of a cardiovascular-risk label expansion for Lilly's Mounjaro. | — | tweet ↗ |
| 2026-08-28 | @bahabreaking | +0.50 | Reports FDA approval of Eli Lilly's Mounjaro for heart disease. | — | tweet ↗ |
| 2026-08-28 | @Cd_Investidores | +0.50 | Reports FDA approval of Mounjaro for cardiovascular-risk reduction and cites trial results. | — | tweet ↗ |
| 2026-08-28 | @BioStocks | +0.50 | FDA approves Mounjaro to reduce cardiovascular risk in adults with type 2 diabetes. | — | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.